Antibody therapeutics company EvoGenix will open its initial public offering within a week and list on the ASX in early to mid-August, with the aim of raising AUD$9 million.
Antibody therapeutics company EvoGenix will open its initial public offering within a week and list on the ASX in early to mid-August, with the aim of raising AUD$9 million.